KING OF PRUSSIA, Pa., March 30, 2026 (GLOBE NEWSWIRE) -- SEED Therapeutics, Inc. (“SEED”) , a clinical-stage biotechnology company specializing in molecular glue degraders, today announced that it ...

Is there a “Super Smash Bros.” movie on the horizon? It sure seems like that’s what “The Super Mario Galaxy Movie” is building up to, with the surprise announcement Thursday that Fox McCloud, of the ...

Student abstract submissions were accepted February 2 - March 23, 2026. Registration to attend will be open throughout the symposium. The Zoom link will be emailed April 1, 2026 or after you register, ...

WALTHAM, Mass., March 20, 2026 (GLOBE NEWSWIRE)-- Sironax, a global clinical-stage biotechnology company developing transformative therapies for neurodegenerative, inflammatory and immunological, ...

For more information and to view the Company’s abstract, visit the AACR Annual Meeting website. The poster will be made available in the Publications section of the Company’s website at the beginning ...

PHILADELPHIA, March 19, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) ...

(MENAFN- GlobeNewsWire - Nasdaq) WESTLAKE VILLAGE, Calif., and DENVER, March 18, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company ...

WESTLAKE VILLAGE, Calif., and DENVER, March 18, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful ...

Copies of the Company’s presentations will be available under the Scientific Presentations tab on the Tonix website at www.tonixpharma.com. About TNX-1700 TNX-1700, a fusion protein of TFF2 and ...

BERKELEY HEIGHTS, N.J., March 17, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully integrated, commercial biotechnology company, today ...

TNX-1700, a fusion protein of TFF2 and albumin, is in preclinical development for the treatment of gastric and colorectal cancer in combination with PD-1 blockade. TNX-1700, in-licensed from Columbia ...

NEW YORK, March 12, 2026 /PRNewswire/ -- Cresilon Inc. ("Cresilon"), a Brooklyn-based biotechnology company focused on hemostatic medical device technologies, today announced that a retrospective ...